Technology area: Biotechnology & Pharmaceuticals
6 pending office actions • 3 art units • 5 examiners • 0 of 6 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days
Quicksilver Scientific Inc. has 6 pending office actions in Biotechnology & Pharmaceuticals. The matters involve 5 examiners across 3 art units, indicating that multiple matters share examiner or art-unit structures rather than occupying wholly separate examination channels.
WHEELER, THURMAN MICHAEL is the busiest examiner, with 2 pending office actions. Those matters provide a practical starting point for coordinated prosecution review, while the remaining assignments should be assessed in light of their individual examination settings.
Based on the USPTO statutory response window for each pending office action. 4 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 4 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 2 (33%) |
| §112 only | 1 (17%) |
| Double-patenting + other | 1 (17%) |
| Multi-statute (no §101) | 1 (17%) |
| No statute on record | 1 (17%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| WHEELER, THURMAN MICHAEL | 2 | 45.8% | +23.5% |
| HOLLOMAN, NANNETTE | 1 | 60.7% | +23.1% |
| MAEWALL, SNIGDHA | 1 | 58.8% | +10.5% |
| WEBB, WALTER E | 1 | 46.3% | +18.8% |
| WAX, ROBERT A | 1 | 25.7% | +3.9% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18615236 | MICROEMULSION DELIVERY SYSTEMS INCORPORATED INTO GUMMY CONFECTIONS | WEBB, WALTER E | 5d overdue |
| 17707067 | Self-Microemulsifying Multi-Deliverable Systems | WAX, ROBERT A | 34d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17967267 | Microemulsion Delivery Systems for A Female Hormone Blend with Alcohol-Soluble Species Including Nonderivatized Hormones | WHEELER, THURMAN MICHAEL | 145d overdue |
| 17672894 | Microemulsion Delivery Systems for Alcohol-Soluble Species Including Nonderivatized Hormones | WHEELER, THURMAN MICHAEL | 38d overdue |
| 18615236 | MICROEMULSION DELIVERY SYSTEMS INCORPORATED INTO GUMMY CONFECTIONS | WEBB, WALTER E | 5d overdue |
| 19083881 | Means For Mitochondrial Performance Enhancement | HOLLOMAN, NANNETTE | — |
| 18891496 | Solid Binding Composition for Toxin Excretion Enhancement | MAEWALL, SNIGDHA | — |
| Art Unit | Apps |
|---|---|
| 1612 | 3 |
| 1619 | 2 |
| 1615 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19083881 | Means For Mitochondrial Performance Enhancement | HOLLOMAN, NANNETTE | 1612 | §103 | Non-Final OA | — | Pending | Mar 19, 2025 |
| 18891496 | Solid Binding Composition for Toxin Excretion Enhancement | MAEWALL, SNIGDHA | 1612 | §103DP | Non-Final OA | — | Pending | Sep 20, 2024 |
| 18615236 | MICROEMULSION DELIVERY SYSTEMS INCORPORATED INTO GUMMY CONFECTIONS | WEBB, WALTER E | 1612 | §103§112 | Final Rejection | 5d overdue | Pending | Mar 25, 2024 |
| 17967267 | Microemulsion Delivery Systems for A Female Hormone Blend with Alcohol-Soluble Species Including Nonderivatized Hormones | WHEELER, THURMAN MICHAEL | 1619 | Other | Final Rejection | 145d overdue | Pending | Oct 17, 2022 |
| 17707067 | Self-Microemulsifying Multi-Deliverable Systems | WAX, ROBERT A | 1615 | §103 | Non-Final OA | 34d | Pending | Mar 29, 2022 |
| 17672894 | Microemulsion Delivery Systems for Alcohol-Soluble Species Including Nonderivatized Hormones | WHEELER, THURMAN MICHAEL | 1619 | §112Other | Final Rejection | 38d overdue | Pending | Feb 16, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialQuicksilver Scientific Inc. has 6 pending office actions as of October 2026, spread across 3 art units and 5 examiners.
Thurman Michael Wheeler has the most, with 2 of Quicksilver Scientific Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
